Overview
- Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Genentech, Gilead, GSK, Merck, Novartis and Sanofi joined earlier signers, bringing the total to 14 companies after prior deals with Pfizer, AstraZeneca, EMD Serono, Novo Nordisk and Eli Lilly.
- The agreements commit manufacturers to Most Favored Nation prices for Medicaid and to introduce new U.S. drugs at that benchmark.
- Participants will list certain primary-care and specialty medicines on the TrumpRx site launching in January, enabling direct cash purchases from manufacturers.
- The nine firms pledged more than $150 billion for U.S. manufacturing and R&D in exchange for a three-year suspension of select import tariffs, and President Trump said he threatened a 10% tariff to secure cooperation.
- Several companies agreed to donate active pharmaceutical ingredients to a national emergency reserve and to formulate finished drugs if needed, and Bristol Myers Squibb said it will donate its anticoagulant Eliquis to Medicaid.